Skip to main content

CORT Corcept Therapeutics Incorporated

Healthcare

quality needs a look, premium valuation.

Quality
Weak
Valuation
Expensive
Key signals
Top-quintile 6-month momentum Filed revenue acceleration
116.10
116.1 Close (USD) Loading candles…

Is Corcept Therapeutics Incorporated a buy? Fundamentals and valuation first

  • Quality is weaker than peers. Operating margin is only around the 37th percentile. TTM ROE is about 7.7%.

  • Valuation is expensive. TTM P/E is in the 99th percentile, above most peers.

  • Recent volatility is elevated. 60-day annualized volatility is in the 72th percentile. Average 20-day dollar volume is about $191.4M.

  • Signals are active now. Top-quintile 6-month momentum, Filed revenue acceleration currently holds; the tables below show what followed in this stock’s own history.

Watchlist

This page refreshes daily after the close. Add Corcept Therapeutics Incorporated to your watchlist to track signal changes on your next visit.

Historical evidence

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

Top-quintile 6-month momentum

Active · now 99.06542056074767%

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

27 historical occurrences (since 2016-07-06)
Average forward return after Top-quintile 6-month momentum。20-day: Win 59.3%, Sample 27, Median +1.9%, Excess -1.81%, Beat mkt rate 48.1%；60-day: Win 46.2%, Sample 26, Median -2.43%, Excess +1.62%, Beat mkt rate 50%；120-day: Win 65.4%, Sample 26, Median +18.09%, Excess +8.85%, Beat mkt rate 57.7%

120 days after: historical avg +17.37%

20-day +0.02%
60-day +4.9%
120-day +17.37%
20-day
60-day
120-day
Win
59.3%
46.2%
65.4%
Sample
27
26
26
Median
+1.9%
-2.43%
+18.09%
Excess
-1.81%
+1.62%
+8.85%
Beat mkt rate
48.1%
50%
57.7%

Over 26 occurrences, 120-day forward avg gained 17.37%, beat the market by 8.85 pts; win rate 65.4%.

Filed revenue acceleration

Active · now 16.022371802033298%

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

13 historical occurrences (since 2018-05-09)
Average forward return after Filed revenue acceleration。20-day: Win 46.2%, Sample 13, Median -4.19%, Excess +1.87%, Beat mkt rate 53.8%；60-day: Win 83.3%, Sample 12, Median +16.31%, Excess +12.46%, Beat mkt rate 83.3%；120-day: Win 75%, Sample 12, Median +36.98%, Excess +23.06%, Beat mkt rate 66.7%

120 days after: historical avg +30.18%

20-day +2.05%
60-day +15.8%
120-day +30.18%
20-day
60-day
120-day
Win
46.2%
83.3%
75%
Sample
13
12
12
Median
-4.19%
+16.31%
+36.98%
Excess
+1.87%
+12.46%
+23.06%
Beat mkt rate
53.8%
83.3%
66.7%

Over 12 occurrences, 120-day forward avg gained 30.18%, beat the market by 23.06 pts; win rate 75%.

Valuation regime and forward returns

Daily TTM P/E is converted into an expanding own-history percentile, then grouped into five valuation regimes. Forward returns use adjusted prices over the next 240 trading days.

PE percentile bandSample days240-day avg returnMedianWin rateAvg excess (vs index)
0-20 10Insufficient data
20-40 79+88.6% +83.8% 100% +47.5%
40-60 386+48.4% +20.7% 93.5% +35.2%
60-80 546+25.4% +8.7% 61.4% +16%
80-100 You are here394+25.4% +28% 70.3% +5.2%

Quarterly EPS is aligned by SEC filing date before it is forward-filled to daily prices. The expanding percentile uses only information available up to each day.

Current TTM P/E is about 276.43, placing it in the 99.5 own-history percentile, inside the 80-100 bucket.

Valuation × momentum analogs

Each historical day is grouped by own-history P/E tercile and 60-day momentum direction, then tested for the next 120-trading-day adjusted return.

Valuation
Momentum
Cheap (own-history bottom third)
Middle
Expensive (own-history top third)
60-day momentum up
Insufficient data
(13d)
+40.8%
Win rate 90.2% Excess +32.1%
234d
Now
+5.9%
Win rate 48.5% Excess -1.3%
637d
60-day momentum down
+61.5%
Win rate 98.4% Excess +39%
63d
+24.8%
Win rate 78.9% Excess +21.8%
304d
+35.8%
Win rate 54.2% Excess +25.1%
284d

Currently in “Expensive (own-history top third) × 60-day momentum up”: across 637 historical days, 120-day forward avg gained 5.9%, win rate 48.5%, lagged the market by 1.3%.

Days = trading days in this bucket; returns use adjusted prices, ex-costs. 60-day momentum: direction of this stock's price over the past 60 trading days.

Market-wide momentum baseline

Across 98,702 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.12%, a 57.8% positive-return rate, and +2.76 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

52-week adjusted-price high

Pending

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

19 times historically; 60-day forward avg +5.16%, win rate 55.6%, beating the market by +4.11 pts on average.

EPS surprise beat

Pending

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

26 times historically; 60-day forward avg +11.8%, win rate 65.2%, beating the market by +7.54 pts on average.

Continue researching Corcept Therapeutics Incorporated with the evidence above.

Continue in Studio ↗

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.